Preimplantation Genetic Testing (PGT)
What are the different types of PGT?
Preimplantation genetic testing for aneuploidy
PGT-A is offered to all IVF patients and looks for extra or missing chromosomes in an embryo. RMA uses the most advanced PGT-A platform available. Validated over several years and rigorous clinical trials, it can detect chromosome abnormalities with more precision than many other platforms. As 50-70% of miscarriages have been shown to be due to chromosome imbalances in an embryo, using PGT-A can substantially reduce these risks.
Preimplantation genetic testing for monogenic/single gene defects
PGT-M is a test available for any patient or couple at risk to have a child with a condition caused by a single gene. Examples include cystic fibrosis, hereditary cancer predispositions or neurofibromatosis. A unique test is developed for every family based on their genetic makeup. RMA works closely with the PGT-M lab to make sure the testing is set up as soon as possible and families have the most accurate results possible.
Preimplantation genetic testing for structural chromosomal rearrangements
The last type, PGT-SR, is an option for couples where one partner has a chromosome rearrangement such as a translocation or inversion. This testing looks for any unbalanced forms of these rearrangements, reducing the chance for a miscarriage and the chance to have a child with a chromosome abnormality.
No matter what type of PGT is done, an embryo biopsy is needed. An embryo biopsy takes place about 5 or 6 days after fertilization of the egg. It involves gently removing about five cells from a part of the embryo that will go on to make the placenta. Embryo biopsy has been shown to be a safe procedure that does not harm the embryo or the baby that develops from it.
A Research Study
Women who have three chromosomally-normal embryos as a result of In Vitro Fertilization (IVF) have a 94.9% chance of achieving pregnancy, new research conducted by Reproductive Medicine Associates (RMA) and presented at the annual meeting of the American Society for Reproductive Medicine (ASRM) shows.